Revvity (RVTY) Stock Price, News & Analysis

Company Overview

Revvity, Inc. is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding. Headquartered in Waltham, Massachusetts, the company maintains a global footprint with R&D, manufacturing and customer support facilities across North America, Europe, Asia-Pacific and Latin America. Its solutions are used by pharmaceutical and biotechnology companies, academic and government research institutions, clinical laboratories, and industrial customers around the world.

Revvity is led by President and Chief Executive Officer Prahlad Singh, who brings extensive experience in the life sciences and diagnostics industries. Under his leadership, the company is focused on advancing its integrated product portfolio, expanding its digital and services offerings, and driving innovation to meet the evolving needs of researchers, clinicians and quality-critical manufacturers globally.

Key Stats

• Today's Range: $85.51 to $88.12
• 50-Day Range: $83.25 to $103.73
• 52-Week Range: $81.36 to $129.50
• Volume: 1.19 million shs
• Average Volume: 1.14 million shs
• Market Capitalization: $10.04 billion
• P/E Ratio: 36.65
• Dividend Yield: 0.32%
• Price Target: $120.07
• Consensus Rating: Moderate Buy

Revvity Stock Analysis - MarketRank™

Revvity scored higher than 74% of companies evaluated by MarketBeat, and ranked 267th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Revvity has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Revvity has a consensus price target of $120.07, representing about 38.8% upside from its current price of $86.50.

Amount of Analyst Coverage

Revvity has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.55%

Earnings Growth

Earnings for Revvity are expected to grow by 12.55% in the coming year, from $4.94 to $5.56 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revvity is 36.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 277.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revvity is 36.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.08.

Price to Earnings Growth Ratio

Revvity has a PEG Ratio of 2.30. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Revvity has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.39% of the float of Revvity has been sold short.

Short Interest Ratio / Days to Cover

Revvity has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Revvity has recently increased by 5.59%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Revvity has a dividend yield of 0.33%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Revvity does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Revvity is 11.86%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Revvity will have a dividend payout ratio of 5.04% next year. This indicates that Revvity will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.39% of the float of Revvity has been sold short.

Short Interest Ratio / Days to Cover

Revvity has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Revvity has recently increased by 5.59%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.30

News Sentiment

Revvity has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Revvity this week, compared to 11 articles on an average week.

Search Interest

Only 1 people have searched for RVTY on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Revvity insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.68% of the stock of Revvity is held by insiders.

Percentage Held by Institutions

86.65% of the stock of Revvity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RVTY Stock Analysis - Frequently Asked Questions

How have RVTY shares performed this year?

Revvity's stock was trading at $111.61 at the beginning of the year. Since then, RVTY stock has decreased by 22.5% and is now trading at $86.50.

How were Revvity's earnings last quarter?

Revvity Inc. (NYSE:RVTY) posted its earnings results on Monday, July, 28th. The company reported $1.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.04. The company's quarterly revenue was up 4.1% compared to the same quarter last year.
Read the conference call transcript.

Is Revvity doing a stock buyback?

Revvity's Board of Directors approved a stock buyback program on Monday, November 4th 2024, which permits the company to repurchase $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 6.5% of its stock through open market purchases. Stock buyback programs are often an indication that the company's management believes its stock is undervalued.

Who are Revvity's major shareholders?

Top institutional shareholders of Revvity include Vanguard Group Inc. (12.14%), EdgePoint Investment Group Inc. (5.85%), State Street Corp (4.32%) and Geode Capital Management LLC (2.52%). Insiders that own company stock include Prahlad R Singh, Joel S Goldberg and Tajinder S Vohra.
View institutional ownership trends.

How do I buy shares of Revvity?

Shares of RVTY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Revvity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Record date for 8/8 Dividend: 7/18/2025
• Ex-Dividend for 8/8 Dividend: 7/18/2025
• Last Earnings: 7/28/2025
• Dividend Payable: 8/08/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NYSE:RVTY
• CIK: 31791
• Web: www.perkinelmer.com
• Phone: (781) 663-6900
• Fax: 781-663-5985
• Employees: 11,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Revvity: $120.07
• High Price Target: $145.00
• Low Price Target: $100.00
• Potential Upside/Downside: +38.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.36
• Trailing P/E Ratio: 36.65
• Forward P/E Ratio: 17.51
• P/E Growth: 2.3
• Net Income: $270.39 million
• Net Margins: 10.19%
• Pretax Margin: 11.29%
• Return on Equity: 7.66%
• Return on Assets: 4.73%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 3.33
• Quick Ratio: 2.75

Sales & Book Value

• Annual Sales: $2.76 billion
• Price / Sales: 3.64
• Cash Flow: $8.60 per share
• Price / Cash Flow: 10.06
• Book Value: $63.00 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 116,070,000
• Free Float: 115,284,000
• Market Cap: $10.04 billion
• Optionable: Optionable
• Beta: 0.94